165 related articles for article (PubMed ID: 35438911)
21. The association between age at breast cancer diagnosis and prevalence of pathogenic variants.
Daly MB; Rosenthal E; Cummings S; Bernhisel R; Kidd J; Hughes E; Gutin A; Meek S; Slavin TP; Kurian AW
Breast Cancer Res Treat; 2023 Jun; 199(3):617-626. PubMed ID: 37084156
[TBL] [Abstract][Full Text] [Related]
22. Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception.
Bychkovsky BL; Lo MT; Yussuf A; Horton C; Hemyari P; LaDuca H; Garber JE; Scheib R; Rana HQ
Breast Cancer Res Treat; 2023 Jul; 200(1):63-72. PubMed ID: 36856935
[TBL] [Abstract][Full Text] [Related]
23. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
Sharma P; Klemp JR; Kimler BF; Mahnken JD; Geier LJ; Khan QJ; Elia M; Connor CS; McGinness MK; Mammen JM; Wagner JL; Ward C; Ranallo L; Knight CJ; Stecklein SR; Jensen RA; Fabian CJ; Godwin AK
Breast Cancer Res Treat; 2014 Jun; 145(3):707-14. PubMed ID: 24807107
[TBL] [Abstract][Full Text] [Related]
24. Postpartum Breast Cancer and Survival in Women With Germline BRCA Pathogenic Variants.
Zhang Z; Ye S; Bernhardt SM; Nelson HD; Velie EM; Borges VF; Woodward ER; Evans DGR; Schedin PJ
JAMA Netw Open; 2024 Apr; 7(4):e247421. PubMed ID: 38639936
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
[TBL] [Abstract][Full Text] [Related]
26.
Incorvaia L; Fanale D; Bono M; Calò V; Fiorino A; Brando C; Corsini LR; Cutaia S; Cancelliere D; Pivetti A; Filorizzo C; La Mantia M; Barraco N; Cusenza S; Badalamenti G; Russo A; Bazan V
Ther Adv Med Oncol; 2020; 12():1758835920975326. PubMed ID: 33403015
[TBL] [Abstract][Full Text] [Related]
27. The Burden of Breast Cancer Predisposition Variants Across The Age Spectrum Among 10 000 Patients.
Chavarri-Guerra Y; Hendricks CB; Brown S; Marcum C; Hander M; Segota ZE; Hake C; Sand S; Slavin TP; Hurria A; Soto-Perez-de-Celis E; Nehoray B; Blankstein KB; Blazer KR; Weitzel JN;
J Am Geriatr Soc; 2019 May; 67(5):884-888. PubMed ID: 31012959
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
ElBiad O; Laraqui A; El Boukhrissi F; Mounjid C; Lamsisi M; Bajjou T; Elannaz H; Lahlou AI; Kouach J; Benchekroune K; Oukabli M; Chahdi H; Ennaji MM; Tanz R; Sbitti Y; Ichou M; Ennibi K; Badaoui B; Sekhsokh Y
BMC Cancer; 2022 Feb; 22(1):208. PubMed ID: 35216584
[TBL] [Abstract][Full Text] [Related]
29. NGS Panel Testing of Triple-Negative Breast Cancer Patients in Cyprus: A Study of
Zanti M; Loizidou MA; Michailidou K; Pirpa P; Machattou C; Marcou Y; Kyriakou F; Kakouri E; Tanteles GA; Spanou E; Spyrou GM; Kyriacou K; Hadjisavvas A
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33120919
[TBL] [Abstract][Full Text] [Related]
30. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
[TBL] [Abstract][Full Text] [Related]
31. Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge.
Bono M; Fanale D; Incorvaia L; Cancelliere D; Fiorino A; Calò V; Dimino A; Filorizzo C; Corsini LR; Brando C; Madonia G; Cucinella A; Scalia R; Barraco N; Guadagni F; Pedone E; Badalamenti G; Russo A; Bazan V
ESMO Open; 2021 Aug; 6(4):100235. PubMed ID: 34371384
[TBL] [Abstract][Full Text] [Related]
32. Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond
Fanale D; Incorvaia L; Filorizzo C; Bono M; Fiorino A; Calò V; Brando C; Corsini LR; Barraco N; Badalamenti G; Russo A; Bazan V
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32854451
[TBL] [Abstract][Full Text] [Related]
33. Detection of germline variants in Brazilian breast cancer patients using multigene panel testing.
Guindalini RSC; Viana DV; Kitajima JPFW; Rocha VM; López RVM; Zheng Y; Freitas É; Monteiro FPM; Valim A; Schlesinger D; Kok F; Olopade OI; Folgueira MAAK
Sci Rep; 2022 Mar; 12(1):4190. PubMed ID: 35264596
[TBL] [Abstract][Full Text] [Related]
34. Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel.
Kwong A; Shin VY; Chen J; Cheuk IWY; Ho CYS; Au CH; Chan KKL; Ngan HYS; Chan TL; Ford JM; Ma ESK
J Mol Diagn; 2020 Apr; 22(4):544-554. PubMed ID: 32068069
[TBL] [Abstract][Full Text] [Related]
35. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
[TBL] [Abstract][Full Text] [Related]
36. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
Front Genet; 2021; 12():674094. PubMed ID: 34917121
[No Abstract] [Full Text] [Related]
37. Association of Family Cancer History With Pathogenic Variants in Specific Breast Cancer Susceptibility Genes.
Kurian AW; Abrahamse P; Ward KC; Hamilton AS; Deapen D; Berek JS; Hoang L; Yussuf A; Dolinsky J; Brown K; Slavin T; Hofer TP; Katz SJ
JCO Precis Oncol; 2021; 5():. PubMed ID: 34977446
[TBL] [Abstract][Full Text] [Related]
38. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
39. Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.
Wong-Brown MW; Avery-Kiejda KA; Bowden NA; Scott RJ
Int J Cancer; 2014 Jan; 134(2):301-5. PubMed ID: 23824750
[TBL] [Abstract][Full Text] [Related]
40. Germline mutations of multiple breast cancer-related genes are differentially associated with triple-negative breast cancers and prognostic factors.
Hata C; Nakaoka H; Xiang Y; Wang D; Yang A; Liu D; Liu F; Zou Q; Wei L; Zheng K; Inoue I; You H
J Hum Genet; 2020 Jul; 65(7):577-587. PubMed ID: 32029870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
